Photo taken from
Rami Manochakian/Twitter
Oct 13, 2023, 17:10
Rami Manochakian: FDA Oncology approves the combination of Encorafenib and Binimetinib for Patients with metastatic Non-Small cell Lung Cancer with a BRAF V600E mutation.
Rami Manochakian, Thoracic medical oncologist at Mayo Clinic, shared on Twitter:
“Hot off the press! FDA Oncology approves the combination of Encorafenib and Binimetinib for Patients with metastatic Non-Small cell Lung Cancer with a BRAF V600E mutation.
Approval is based on PHAROS trial (an open-label, multicenter, single-arm study) which showed:
- ORR in treatment naive patients: 75%
mDoR: Not estimable - ORR in previously treated patients: 46%
mDoR: 16.7 months”
For the article click here.
Source: Rami Manochakian/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 19, 2024, 13:35
Dec 19, 2024, 12:39
Dec 19, 2024, 12:20
Dec 19, 2024, 12:01
Dec 19, 2024, 11:58
Dec 19, 2024, 11:54
Dec 19, 2024, 11:53